Finance

Lists
LSTA:NASDAQ
Lisata Therapeutics, Inc.
1,10ย $
+0,92%
(+0,0100) 1D
17 ีถีธีต, 11:02:02 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LSTA...
Open
1,08ย $
High
1,10ย $
Low
1,00ย $
Mkt. cap
11,88ย ีดีฌีถ
Avg. vol.
135,12ย ีฐีฆึ€
Volume
224,84ย ีฐีฆึ€
52-wk high
5,07ย $
52-wk low
0,96ย $
EPS
-1,64ย $
Beta
1,04
Shares outstanding
10,80ย ีดีฌีถ
No. of employees
21
Open
1,08ย $
High
1,10ย $
Low
1,00ย $
Mkt. cap
11,88ย ีดีฌีถ
Avg. vol.
135,12ย ีฐีฆึ€
Volume
224,84ย ีฐีฆึ€
52-wk high
5,07ย $
52-wk low
0,96ย $
EPS
-1,64ย $
Beta
1,04
Shares outstanding
10,80ย ีดีฌีถ
No. of employees
21
News stories
From web sources and news partners
ChartMill
ChartMill
·
55 ึ€ีธีบีฅ ีกีผีกีป
S&P 500 Stocks Gapping Down in Today's Session
TradingView
TradingView
·
1 ีชีกีด ีกีผีกีป
Wells Fargo sets 2027 S&P 500 year-end target at 8,200
Gadget Review
Gadget Review
·
1 ีชีกีด ีกีผีกีป
Nearly 10% of the S&P 500 Depends on Just Three Men With No Clear Successors
Traders Union
Traders Union
·
15 ึ€ีธีบีฅ ีกีผีกีป
S&P 500 trades near AVWAP and key retracement lines, Chris Ciovacco notes
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, ี†ีตีธึ‚ ี‹ีฅึ€ีฝีซ, ี„ีซีกึีตีกีฌ ี†ีกีฐีกีถีฃีถีฅึ€
SectorHealth Care
Industry-
Websitelisata.com
Analyst
Recommendation
Action
Price target
Projected
Date
Kemp Dolliver
Brookline Capital Markets
Hold
Downgraded
-
-
07/27/2026
Joseph Pantginis
H.C. Wainwright
Hold
Downgraded
-
-
05/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ีฉ. ีคีฅีฏ
2026 ีฉ. ีดึ€ีฟ
2026 ีฉ. ีฐีถีฝ
2026 ีฉ. ีฝีฅีบ
Revenue
100,00ย ีฐีฆึ€
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1,13ย ีดีฌีถ
1,20ย ีดีฌีถ
584,00ย ีฐีฆึ€
5,21ย ีดีฌีถ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,04ย ีดีฌีถ
3,74ย ีดีฌีถ
3,41ย ีดีฌีถ
4,82ย ีดีฌีถ
Operating expense
3,18ย ีดีฌีถ
4,94ย ีดีฌีถ
3,99ย ีดีฌีถ
10,03ย ีดีฌีถ
Total operating expenses
3,18ย ีดีฌีถ
4,94ย ีดีฌีถ
3,99ย ีดีฌีถ
10,03ย ีดีฌีถ
Operating income
-3,08ย ีดีฌีถ
-4,94ย ีดีฌีถ
-3,99ย ีดีฌีถ
-10,03ย ีดีฌีถ
Other non operating income
-16,00ย ีฐีฆึ€
-16,00ย ีฐีฆึ€
984,00ย ีฐีฆึ€
-3,06ย ีดีฌีถ
EBT including unusual items
-2,95ย ีดีฌีถ
-4,88ย ีดีฌีถ
-2,93ย ีดีฌีถ
-12,81ย ีดีฌีถ
EBT excluding unusual items
-2,95ย ีดีฌีถ
-4,84ย ีดีฌีถ
-2,93ย ีดีฌีถ
-12,81ย ีดีฌีถ
Income tax expense
-
-387,00ย ีฐีฆึ€
-
-6,03ย ีดีฌีถ
Effective tax rate
-
7,94%
-
47,03%
Other operating expenses
-
-
-
-
Net income
-2,95ย ีดีฌีถ
-4,49ย ีดีฌีถ
-2,93ย ีดีฌีถ
-6,79ย ีดีฌีถ
Net profit margin
-2ย 954,00%
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
141,00ย ีฐีฆึ€
120,00ย ีฐีฆึ€
79,00ย ีฐีฆึ€
273,00ย ีฐีฆึ€
Interest expense
-
-
-
-
Net interest expenses
141,00ย ีฐีฆึ€
120,00ย ีฐีฆึ€
79,00ย ีฐีฆึ€
273,00ย ีฐีฆึ€
Depreciation and amortization charges
-
-
-
-
EBITDA
-3,06ย ีดีฌีถ
-4,94ย ีดีฌีถ
-3,99ย ีดีฌีถ
-10,03ย ีดีฌีถ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps